Why Botanix Pharmaceuticals Ltd shares rocketed 61% higher today

In morning trade the Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been one of the best performers on the local market with a huge move higher.

At the time of writing the dermatology company’s shares are up 61% to 21 cents.

What happened?

This morning Botanix advised that it has successfully completed a Phase 1b study in patients with moderate to severe acne.

According to the release, the study met all designated endpoints and large reductions in acne lesions were observed after four weeks of treatment. Pleasingly, the treatment was significantly better than the current leading topical acne products.

In addition to this, the topical application of BTX 1503 was safe and very well-tolerated, with no reported signs of skin irritation.

As a result, the company plans to rapidly advance BTX 1503 into a Phase 2 acne patient study in North America and Australia in the second-quarter of calendar year 2018.

What is BTX 1503?

BTX 1503 is a topically applied synthetic cannabidiol acne product that offers localised delivery areas on the skin with the disease. For this reason Botanix is often categorized as a medicinal cannabis company alongside the likes of Auscann Group Holdings Ltd (ASX: AC8), Hydroponics Company Ltd (ASX: THC), and MGC Pharmaceuticals Ltd (ASX: MXC).

Should you invest?

As I have said previously, I feel Botanix could have an extremely bright future thanks to its BTX 1503 product and Permetrex proprietary drug delivery system.

After all, the acne prescription market is expected to be worth up to US$4.5 billion per year by 2018 and current oral treatments have horrific side effects.

However, a phase 2 trial will not be cheap and the company may need to raise funds for it in my opinion. But considering this positive news, I don’t think it will be short of support from institutional investors.

If you like exciting shares like Botanix then I think you'll love these fast-growing shares.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.